logo

Caladrius Biosciences, Inc. (CLBS)



Trade CLBS now with
  Date
  Headline
7/15/2019 8:40:44 AM Caladrius Biosciences Says EMA Grants Advanced Therapy Medicinal Product Classification For CLBS12
6/4/2019 8:38:17 AM Caladrius Biosciences Completes Enrollment In Phase 2 ESCaPE-CMD Trial For Coronary Microvascular Dysfunction
5/14/2019 6:43:19 AM WBB Securities Starts Caladrius Biosciences, Inc. (CLBS) At Speculative Buy With $6.75 Price Target
11/8/2018 8:32:16 AM Caladrius Biosciences Appoints Cynthia Schwalm To Board
6/19/2018 8:04:25 AM Caladrius Gets FDA Regenerative Medicine Advanced Therapy Designation For CD34+ Cell Therapy For Refractory Angina
5/10/2018 4:09:52 PM Caladrius Biosciences Q1 Net Loss From Cont Ops $5.0 Mln Or $0.52 Per Share
4/10/2018 8:04:22 AM Caladrius Biosciences Receives SAKIGAKE Expedited Review Designation In Japan For CLBS12 For Critical Limb Ischemia
3/22/2018 4:08:37 PM Caladrius Biosciences Q4 Loss/share $0.29 Vs. Loss $0.73 Year Ago
3/13/2018 8:04:54 AM Caladrius Biosciences Doses First Patient With CLBS12 In Phase 2 Critical Limb Ischemia Trial In Japan
3/6/2018 8:05:34 AM Caladrius Acquires License To Late Stage CD34+ Cell Therapy Program For Treatment Of Refractory Angina
  
 
>